#1 Clinical Trials Search in Europe

Study Comparing Subcutaneous and Intravenous Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

3 1 1 1

What is this study about?

This clinical trial is focused on studying the treatment of metastatic non-small cell lung cancer (NSCLC), which is a type of lung cancer that has spread to other parts of the body. The study is investigating the use of a medication called pembrolizumab, also known by its code name MK-3475, in combination with chemotherapy drugs. The chemotherapy drugs involved in this study include cisplatin, carboplatin, paclitaxel, paclitaxel albumin-bound, and pemetrexed. Pembrolizumab is a type of treatment known as immunotherapy, which helps the immune system fight cancer.

The purpose of this study is to compare two different ways of giving pembrolizumab: as a subcutaneous injection (under the skin) and as an intravenous infusion (through a vein). Participants will receive pembrolizumab along with one of the chemotherapy drugs as part of their first-line treatment, which means it is the first treatment given for their cancer. The study will help determine how the body processes pembrolizumab when given in these two different ways and will also look at the safety of these treatments.

Participants in the study will receive treatment over a period of time, with regular visits to the clinic for their medication and monitoring. The study will track how well the cancer responds to the treatment and any side effects that may occur. This information will help doctors understand the best way to use pembrolizumab in combination with chemotherapy for treating metastatic non-small cell lung cancer.

1 initial treatment phase

The study begins with the administration of pembrolizumab, a medication used to treat certain types of cancer. It is given either as a subcutaneous injection or an intravenous infusion. The method of administration is determined by the study group to which the participant is assigned.

In addition to pembrolizumab, participants receive a combination of chemotherapy drugs. These include cisplatin or carboplatin, and paclitaxel or paclitaxel albumin-bound. These drugs are administered through intravenous infusion.

The treatment is repeated in cycles, with each cycle lasting three weeks. The exact dosage and frequency depend on the specific protocol of the study.

2 monitoring and assessment

Throughout the trial, regular monitoring is conducted to assess the body’s response to the treatment. This includes measuring the concentration of pembrolizumab in the blood at various points, such as at the end of the first and sixth cycles.

Participants undergo imaging tests to evaluate the size and progression of the cancer. These tests help determine the objective response rate, which is the percentage of participants whose cancer shrinks or disappears after treatment.

3 safety evaluation

The safety of the treatment is closely monitored. Any side effects or adverse events experienced by participants are recorded and evaluated.

Participants are assessed for the presence of anti-drug antibodies, which can develop in response to pembrolizumab and potentially affect its effectiveness.

4 long-term follow-up

After completing the treatment cycles, participants enter a follow-up phase. This phase involves regular check-ups to monitor overall health and any long-term effects of the treatment.

The study aims to measure progression-free survival and overall survival, which are indicators of how long participants live without the cancer worsening and the overall length of survival, respectively.

Who Can Join the Study?

  • The patient must have a confirmed diagnosis of a type of lung cancer called non-small cell lung cancer (NSCLC), which can be either squamous or nonsquamous.
  • The patient must have adequate organ function, meaning their organs are working well enough to participate in the study.
  • The patient must have Stage IV NSCLC, which means the cancer has spread to other parts of the body.
  • The patient must have confirmation that certain treatments, like those targeting EGFR, ALK, or ROS1, are not suitable for their type of lung cancer.
  • The patient must not have received previous treatments that affect the whole body for their metastatic NSCLC. If they had treatments before, it must have been at least 12 months before the cancer spread.
  • The patient must have an ECOG performance score of 0 or 1, which indicates they are fully active or have some symptoms but can still carry out light work.
  • Male patients must agree to use contraception unless they are confirmed to be azoospermic, meaning they do not produce sperm.
  • Female patients must not be pregnant or breastfeeding. If they can have children, they must agree to use contraception.
  • The patient must have measurable disease according to specific criteria used to evaluate tumors.
  • The patient must provide a sample of their tumor tissue for testing before being randomly assigned to a treatment group.

Who Cannot Join the Study?

  • Patients with other types of cancer besides metastatic non-small cell lung cancer cannot participate. Metastatic means the cancer has spread to other parts of the body.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are part of a vulnerable population, which means they might need special protection or care, cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Szpital Wojewodzki Im. Mikolaja Kopernika W Koszalinie Koszalin Poland
Koranyi National Institute For Pulmonology Budapest Hungary

Other Sites

Site Name City Country Status
Centrum Onkologii Im. Prof. Franciszka Lukaszczyka W Bydgoszczy Bydgoszcz Poland
Hospital Foch Suresnes France
Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet Szolnok Hungary
Radiotherapy Center Cluj S.R.L. Floresti Romania
Complejo Hospitalario Universitario Insular Materno Infantil Las Palmas De Gran Canaria Spain
Centrum Pulmonologii I Torakochirurgii W Bystrej Wilkowice Poland
Centrul De Oncologie SF Nectarie S.R.L. Craiova Romania
Semmelweis University Budapest Hungary
Spitalul Universitar De Urgenta Bucuresti Bucharest Romania
Oncomed S.R.L. Timisoara Romania
Zala Megyei Szent Rafael Korhaz Zalaegerszeg Hungary
Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca Cluj Napoca Romania
Tuedogyogyintezet Toeroekbalint Torokbalint Hungary
Cardiomed S.R.L. Cluj Napoca Romania
Spitalul De Oncologie Monza S.R.L. Bucharest Romania
Hopital Beaujon Clichy France
Bbxewxuyrsy Vynqushqv Ojosamezaxfw Kecskemet Hungary
Pdfqpevisgu Lmiagykp &iuubffcdkxlsjarvjiq Rvvjk Kzffpqqvuwc Konin Poland
Codqwg Hjrvgdsfsto Ej Uyzmcqcnvnemh Dt Lhphfxi Limoges France
Ndryibvj Izjqypah Owuoevduh Iok Mhbpx Sgwvwjqvrcnqdnwttjxuccqksdeb Irfchtmb Bvmwhmss Cracow Poland
Fjxuhxzoi Pxzc La Irwhbcqhmbduy Behfeniqq Dnp Hsvuvdux Uvkhomcuomvrk Lo Pcr Madrid Spain
Hxwzjlsl Vsyv dpnisqpl Barcelona Spain
Hghboyzv Uzddcxduatkpea Sauzrowxib &ylfaqt Hutyutu dz Hxcjwbuebry STRASBOURG, Alsace France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not recruiting
30.07.2021
Hungary Hungary
Not recruiting
30.07.2021
Poland Poland
Not recruiting
30.07.2021
Romania Romania
Not recruiting
30.07.2021
Spain Spain
Not recruiting
30.07.2021

Trial locations

Investigated drugs:

Pembrolizumab: This medication is used to treat certain types of cancer by helping the immune system fight cancer cells. In this trial, it is being studied in two different forms of administration: subcutaneous (under the skin) and intravenous (into a vein). The goal is to compare how the body absorbs and processes the medication in these two forms.

Platinum Doublet Chemotherapy: This is a combination of two chemotherapy drugs that are often used together to treat lung cancer. These medications work by killing or stopping the growth of cancer cells. In this trial, platinum doublet chemotherapy is used alongside pembrolizumab to see how effective the combination is in treating metastatic non-small-cell lung cancer.

Investigated diseases:

Metastatic (stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC) – This is a type of lung cancer that has spread beyond the lungs to other parts of the body. It originates in the cells lining the airways and can be classified into squamous or nonsquamous types based on the cell characteristics. As the disease progresses, it can invade nearby tissues and organs, leading to a range of symptoms such as persistent cough, chest pain, and difficulty breathing. The cancer cells can travel through the bloodstream or lymphatic system, forming new tumors in distant organs. This stage of cancer is considered advanced, as it indicates that the cancer has metastasized, or spread, beyond its original site.

Trial ID:
2023-508308-40-00
Protocol code:
MK-3475-A86
NCT ID:
NCT04956692
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study on the Safety and Effects of VERT-002 for Patients with Advanced Solid Tumors, Including Lung Cancer with MET Alterations

    Recruiting

    2 1 1
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Spain

  • Evaluation of mRNA-4359 Monotherapy and Combined Pembrolizumab Therapy in Advanced Solid Tumors: A Phase 1/2 Clinical Trial

    Recruiting

    2 1 1 1
    Investigated drugs:
    Germany Italy Poland Spain